Fatigue therapy in multiple sclerosis

Abstract

Amantadine was significantly better than placebo in treating fatigue in MS patients, whereas pemoline was not. The benefit of amantadine was not due to changes in sleep, depression, or neurologic disability.

Fatigue and cancer: causes, prevalence and treatment approaches

“…Weinshenker et al (1992) evaluated pemoline for the treatment of fatigue among patients with multiple sclerosis and found a trend suggesting reduced fatigue among patients who received pemoline compared to placebo (Po 0.06). Krupp et al (1995) conducted a randomised, clinical trial to compare amantadine, pemoline, or placebo for the treatment of fatigue in patients with multiple sclerosis. Patients who received amantadine had significantly less fatigue compared to those receiving pemoline or placebo.…”

Les syndromes de fatigue d'origine cérébrale

“…Plusieurs substances ont cependant été testées. L'amantadine (qui possède des effets antiviraux et antiparkinsoniens) semble induire une réduction modeste mais significative de la fatigue, contrairement à la pemoline (stimulant du SNC) qui se révèle inefficace avec de fréquents effets secondaires [33]. Les résultats avec la 3,4-diaminopyridine (bloque les canaux potassiques, prolongeant ainsi la durée du potentiel d'action et améliorant le facteur de sécurité de la transmission nerveuse) sont hétérogènes [34].…”

Multi̇pl Sklerozda Semptomati̇k Tedavi̇

“…"Halsizlik" tipi yorgunluğun tedavisi için yıllarca uyarıcı maddeler kullanılmıştır (6). Son yıllarda MS'de amanfadin (31) ve pemolin'in yorgunluk üzerine etkisi olduğu bildirilmiştir (6,32).…”

“…Amantadin ve pemolinin plasebo ile karşılaştırıldığında MS'te bilişsel işlevleri arttırmadığı bildirilmiştir (32). Bilişsel terapi de MS'in bazı semptomlarını düzelterek umut verici bir tedavi yöntemi olarak görünmektedir (33).…”